Sarepta Therapeutics (SRPT) Tops Q2 EPS by 42c, Beats on Revenue

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $0.64, $0.42 better than the analyst estimate of $0.22. Revenue for the quarter came in at $401.3 million versus the consensus estimate of $383 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral